BioSpace News Archive

38th Annual Canaccord Genuity Growth Conference on Wednesday, August 8th at 12:30 pm ET being held in Boston, Massachusetts.

Neovasc Inc. announced publication of the manuscript, “Safety and efficacy of the Reducer: A multicenter clinical registry - REDUCE study” in the International Journal of Cardiology

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced the appointment of several key members to its commercial leadership team.

Mallinckrodt to fund up to $10 million in collaborative research programs over five years to focus on rare diseases

Dr. Lo is a preeminent physician-scientist widely recognized for his work in understanding treatment-resistant melanoma

Pliant Therapeutics, Inc., a biotechnology company focused on discovering, developing and commercializing treatments for fibrotic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for the company’s anti-fibrotic lead compound, PLN-74809, for the treatment of idiopathic pulmonary fibrosis (IPF).

Substantial Reduction in CytRx Cash Burn Rate This Quarter

Cure Genetics Co., Ltd announced the closing of $17 million Series A financing, led by Qiming Venture Partners.

Aridis Pharmaceuticals, Inc. today announced that it has launched an initial public offering of 2,000,000 shares of its common stock.

Immune Biosolutions Inc. announced a research collaboration and license agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.